BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26124319)

  • 1. Systematic Review of Candidate Single-nucleotide Polymorphisms as Biomarkers for Responsiveness to Neoadjuvant Chemoradiation for Rectal Cancer.
    Maring ED; Tawadros PS; Steer CJ; Lee JT
    Anticancer Res; 2015 Jul; 35(7):3761-6. PubMed ID: 26124319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer.
    Nelson B; Carter JV; Eichenberger MR; Netz U; Galandiuk S
    Surgery; 2016 Nov; 160(5):1326-1332. PubMed ID: 27423551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
    Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
    Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.
    Dreussi E; Cecchin E; Polesel J; Canzonieri V; Agostini M; Boso C; Belluco C; Buonadonna A; Lonardi S; Bergamo F; Gagno S; De Mattia E; Pucciarelli S; De Paoli A; Toffoli G
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.
    Dayde D; Tanaka I; Jain R; Tai MC; Taguchi A
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.
    Kim SY; Baek JY; Oh JH; Park SC; Sohn DK; Kim MJ; Chang HJ; Kong SY; Kim DY
    Radiat Oncol; 2017 Mar; 12(1):62. PubMed ID: 28347333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.
    Ryan JE; Warrier SK; Lynch AC; Heriot AG
    Colorectal Dis; 2015 Oct; 17(10):849-61. PubMed ID: 26260213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.
    Ryan JE; Warrier SK; Lynch AC; Ramsay RG; Phillips WA; Heriot AG
    Colorectal Dis; 2016 Mar; 18(3):234-46. PubMed ID: 26531759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
    Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
    Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized threshold for tumor segmentation in 18F-FDG PET/CT imaging: The key for response evaluation of neoadjuvant chemoradiation therapy in patients with rectal cancer?
    Fagundes TC; Mafra A; Silva RG; Castro ACG; Silva LC; Aguiar PT; Silva JA; P Junior E; Machado AM; Mamede M
    Rev Assoc Med Bras (1992); 2018 Feb; 64(2):119-126. PubMed ID: 29641665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
    Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
    Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review.
    Pezzolo E; Modena Y; Corso B; Giusti P; Gusella M
    Eur J Clin Pharmacol; 2015 May; 71(5):529-39. PubMed ID: 25740678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Lim SH; Chua W; Henderson C; Ng W; Shin JS; Chantrill L; Asghari R; Lee CS; Spring KJ; de Souza P
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):67-80. PubMed ID: 26032919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
    Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
    BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MTHFR C677T Polymorphism is Associated with Tumor Response to Preoperative Chemoradiotherapy: A Result Based on Previous Reports.
    Zhao Y; Li X; Kong X
    Med Sci Monit; 2015 Oct; 21():3068-76. PubMed ID: 26456456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.